Vistagen Therapeutics (VTGN) Other Non Operating Income (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Other Non Operating Income of -$2000.0 for Q1 2026, down 133.33% sequentially from $6000.0 in Q3 2025, and down 140.0% YoY from $5000.0 in Q1 2025.
Vistagen Therapeutics (VTGN) Other Non Operating Income (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Other Non Operating Income for 9 years, with the latest figure at -$2000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 140.0% year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2000.0 (down 60.0% YoY) and the FY2026 annual result came in at $7000.0, up 40.0% from the prior year.
- Other Non Operating Income eased to -$2000.0 in Q1 2026 per VTGN's latest filing, from $6000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $6000.0 in Q3 2025 and troughed at -$2000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | -2,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2018 | -22,700.00 |
| Dec 31, 2017 | -135,000.00 |
| Sep 30, 2015 | -1.65 Mn |
| Jun 30, 2014 | -768,000.00 |
| Mar 31, 2013 | -31,000.00 |
| Dec 31, 2012 | -3.54 Mn |
| Dec 31, 2011 | -1.19 Mn |